Presented with neurologists at Nagoya University at the 52nd Annual Meeting of the Japanese Society for Mass Screening. A version of the same assay also screens for severe combined immunodeficiency from a cord blood sample.
TOKYO, October 14, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, presented research on a rapid bedside dual screening tool for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) at the 52nd Annual Meeting of the Japanese Society for Mass Screening.
In a prospective study of 1,300 newborns, the SMA screening tool returned a result within 1.5 hours of birth from a saliva sample and agreed with confirmatory MLPA diagnostic testing in every case.
The work was done with Professor Masahisa Katsuno and Associate Professor Kentaro Sahashi of the Department of Neurology at Nagoya University. The presentation was titled "Development of a rapid bedside dual screening tool for spinal muscular atrophy and severe combined immunodeficiency."
This work is newborn screening. It is separate from Craif's urine microRNA cancer testing business, and nothing in this study involves cancer detection.
What the team reported at the meeting
- Turnaround. Conventional SMA screening has required one to two weeks after birth for a result to come back. The new tool uses a saliva sample, runs at the bedside, and returns a result within 1.5 hours.
- Agreement with confirmatory testing. In a prospective study at cooperating obstetric facilities, the team tested 1,300 newborns whose guardians consented. Results agreed with confirmatory MLPA testing in every case.
- Workload at the point of care. When obstetric facility staff ran the full procedure themselves, hands-on time was under one minute, and results matched the laboratory, with no special training. In a survey, staff rated the burden as comparable to or lighter than other tests and procedures they already perform.
- One run, two conditions. The team also built an assay targeting TREC (T-cell receptor excision circles), which is produced when T lymphocytes are generated, for SCID. Combining the two produced a system that screens for SMA and SCID simultaneously, directly from an umbilical cord blood sample.
Why turnaround matters in SMA
SMA is a refractory disease in which motor neurons are impaired from birth. Recent treatments can improve motor function and survival, but their benefit is limited when treatment starts after symptoms appear, which makes finding and treating infants while they are still asymptomatic critical.
The team set out to build an ultra-rapid SMA screening tool that an obstetric facility could run itself, and worked with cooperating institutions to assess whether it could be deployed in practice. The tool was designed so that SCID screening could run alongside SMA screening, and the team examined the feasibility of an assay incorporating TREC.
How the study was run
At participating obstetric facilities, saliva and umbilical cord blood samples were collected from 1,300 newborns already undergoing expanded newborn screening, with guardian consent. The team anonymized the samples and analyzed them with both the new tool and MLPA. Results agreed in every case.
Obstetric facility staff also ran the full test procedure so the team could assess whether a hospital could adopt it. Even with no special training, hands-on time was under one minute, and the results matched those obtained in the laboratory.
The team then evaluated the combined SMA and SCID assay with TREC primers added. With each primer concentration optimized, the assay correctly and simultaneously distinguished low-TREC samples, defined as fewer than 10 TREC copies per reaction, and SMA-positive samples.
Unlike conventional methods, the tool requires no specialized testing instrument, and SMA screening can be run simply at the bedside within 1.5 hours of birth. The team describes it as a potentially useful way to get the most benefit from treatment.
Research status
This work was presented at a scientific meeting and has not been published in a peer-reviewed journal. The tool is a research tool, and no regulatory claim is made in Japan or the United States.
This presentation builds on results Craif has previously reported for the same screening tool, including a presentation at Cure SMA 2025 in a cohort of 1,000 newborns. New here are the larger 1,300-newborn cohort, the obstetric staff workload data, and the combined SMA and SCID system run directly from cord blood.
Craif plans a prospective study using clinical specimens for the kit that screens for SMA and SCID together.
About the 52nd Annual Meeting of the Japanese Society for Mass Screening
- Dates: October 3 to October 4, 2025
- Venue: Winc Aichi, Nagoya, Aichi Prefecture
- Official site: https://jsns52.umin.jp
About Craif
Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.
